Sangamo BioSciences Stock News

Sangamo and licensee Pfizer's SB-525 is competing with BioMarin's ValRox in hemophilia A. There are durability questions surrounding both drugs.

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2021 Results - Earnings Call Transcript

Sangamo (SGMO) delivered earnings and revenue surprises of -10.34% and -17.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in fireside chats at the following inves

Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Medicines Agency's Committee for Orphan Medicinal Products (

Genomic medicine collaborations are a valuable method of risk mitigation. They also are a source of funding which can be used to build a deeper pipeline. Sangamo is leveraging many pharmaceutical lead

The stock price of Sangamo Therapeutics, a biotechnology company that focuses on multiple areas in the genomic medicine space, including gene therapy, cell therapy, in vivo genome editing, and in vivo

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2020 Results - Earnings Call Transcript

Sangamo (SGMO) delivered earnings and revenue surprises of -61.11% and -31.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, as Senior Vice President and Hea

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new o

Sangamo: 'Good Companies Get Bought, Not Sold'